Product Code: ETC9959367 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Antivenoms Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Antivenoms Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Antivenoms Market - Industry Life Cycle |
3.4 United States (US) Antivenoms Market - Porter's Five Forces |
3.5 United States (US) Antivenoms Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 United States (US) Antivenoms Market Revenues & Volume Share, By Species, 2021 & 2031F |
3.7 United States (US) Antivenoms Market Revenues & Volume Share, By Mode of Action, 2021 & 2031F |
3.8 United States (US) Antivenoms Market Revenues & Volume Share, By End-User, 2021 & 2031F |
4 United States (US) Antivenoms Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of snake bites in the United States |
4.2.2 Growing awareness about the importance of rapid treatment with antivenoms |
4.2.3 Advancements in technology leading to the development of more effective antivenoms |
4.3 Market Restraints |
4.3.1 Regulatory challenges in the approval and distribution of antivenoms |
4.3.2 Limited availability of specialized healthcare facilities for snake bite treatment |
4.3.3 High cost associated with antivenom treatments |
5 United States (US) Antivenoms Market Trends |
6 United States (US) Antivenoms Market, By Types |
6.1 United States (US) Antivenoms Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Antivenoms Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 United States (US) Antivenoms Market Revenues & Volume, By Polyvalent, 2021- 2031F |
6.1.4 United States (US) Antivenoms Market Revenues & Volume, By Monovalent, 2021- 2031F |
6.1.5 United States (US) Antivenoms Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United States (US) Antivenoms Market, By Species |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Antivenoms Market Revenues & Volume, By Snake, 2021- 2031F |
6.2.3 United States (US) Antivenoms Market Revenues & Volume, By Spider, 2021- 2031F |
6.2.4 United States (US) Antivenoms Market Revenues & Volume, By Scorpion, 2021- 2031F |
6.2.5 United States (US) Antivenoms Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Antivenoms Market, By Mode of Action |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Antivenoms Market Revenues & Volume, By Cytotoxic, 2021- 2031F |
6.3.3 United States (US) Antivenoms Market Revenues & Volume, By Neurotoxic, 2021- 2031F |
6.3.4 United States (US) Antivenoms Market Revenues & Volume, By Haemotoxic, 2021- 2031F |
6.3.5 United States (US) Antivenoms Market Revenues & Volume, By Cardiotoxic, 2021- 2031F |
6.3.6 United States (US) Antivenoms Market Revenues & Volume, By Myotoxic, 2021- 2031F |
6.3.7 United States (US) Antivenoms Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Antivenoms Market, By End-User |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Antivenoms Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.3 United States (US) Antivenoms Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.4 United States (US) Antivenoms Market Revenues & Volume, By Ambulatory surgical centers, 2021- 2031F |
6.4.5 United States (US) Antivenoms Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Antivenoms Market Import-Export Trade Statistics |
7.1 United States (US) Antivenoms Market Export to Major Countries |
7.2 United States (US) Antivenoms Market Imports from Major Countries |
8 United States (US) Antivenoms Market Key Performance Indicators |
8.1 Average time from diagnosis to administration of antivenom |
8.2 Number of research studies and clinical trials on new antivenom products |
8.3 Percentage of healthcare professionals trained in snake bite management and antivenom administration |
9 United States (US) Antivenoms Market - Opportunity Assessment |
9.1 United States (US) Antivenoms Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 United States (US) Antivenoms Market Opportunity Assessment, By Species, 2021 & 2031F |
9.3 United States (US) Antivenoms Market Opportunity Assessment, By Mode of Action, 2021 & 2031F |
9.4 United States (US) Antivenoms Market Opportunity Assessment, By End-User, 2021 & 2031F |
10 United States (US) Antivenoms Market - Competitive Landscape |
10.1 United States (US) Antivenoms Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Antivenoms Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |